UA80561C2 - Substituted tetralins and indanes and use thereof - Google Patents

Substituted tetralins and indanes and use thereof Download PDF

Info

Publication number: UA80561C2
Authority: UA; Ukraine
Prior art keywords: ylsulfanyl; ureido; item; differs; compound according
Prior art date: 2002-10-21

Application number

UAA200503454A

Other languages

English (en)

Ukrainian (uk)

Original Assignee

Janssen Pharmaceutica Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-10-21

Filing date

2003-10-17

Publication date

2007-10-10

2003-10-17 Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv

2007-10-10 Publication of UA80561C2 publication Critical patent/UA80561C2/uk

Links

125000003392 indanyl group Chemical class C1(CCC2=CC=CC=C12)* 0.000 title abstract 2
125000005329 tetralinyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 title 1
238000000034 method Methods 0.000 abstract description 13
239000000203 mixture Substances 0.000 abstract description 4
206010012601 diabetes mellitus Diseases 0.000 abstract description 3
CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 abstract 3
125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 33
150000001875 compounds Chemical class 0.000 description 32
KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 17
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 16
-1 phenyl-O- Chemical class 0.000 description 16
125000000217 alkyl group Chemical group 0.000 description 14
235000019260 propionic acid Nutrition 0.000 description 8
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 8
125000003545 alkoxy group Chemical group 0.000 description 5
239000003472 antidiabetic agent Substances 0.000 description 5
229940125708 antidiabetic agent Drugs 0.000 description 5
230000001404 mediated effect Effects 0.000 description 5
239000002253 acid Substances 0.000 description 4
125000002947 alkylene group Chemical group 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
201000010099 disease Diseases 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
125000005843 halogen group Chemical group 0.000 description 4
208000001072 type 2 diabetes mellitus Diseases 0.000 description 4
206010060378 Hyperinsulinaemia Diseases 0.000 description 3
206010022489 Insulin Resistance Diseases 0.000 description 3
125000004414 alkyl thio group Chemical group 0.000 description 3
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
230000003451 hyperinsulinaemic effect Effects 0.000 description 3
201000008980 hyperinsulinism Diseases 0.000 description 3
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
206010061818 Disease progression Diseases 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
239000013543 active substance Substances 0.000 description 2
230000005750 disease progression Effects 0.000 description 2
239000008103 glucose Substances 0.000 description 2
125000005842 heteroatom Chemical group 0.000 description 2
125000000623 heterocyclic group Chemical group 0.000 description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
201000001421 hyperglycemia Diseases 0.000 description 2
PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 2
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
208000002705 Glucose Intolerance Diseases 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
208000017442 Retinal disease Diseases 0.000 description 1
206010038923 Retinopathy Diseases 0.000 description 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
125000005256 alkoxyacyl group Chemical group 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
125000004093 cyano group Chemical group *C#N 0.000 description 1
125000000753 cycloalkyl group Chemical group 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 1
125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
125000001183 hydrocarbyl group Chemical group 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
201000001119 neuropathy Diseases 0.000 description 1
230000007823 neuropathy Effects 0.000 description 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
208000033808 peripheral neuropathy Diseases 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
201000009104 prediabetes syndrome Diseases 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
- C07C271/56—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/32—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
- C07C275/34—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms having nitrogen atoms of urea groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
- C07C323/43—Y being a hetero atom
- C07C323/44—X or Y being nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/61—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Diabetes (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Obesity (AREA)
Endocrinology (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Ophthalmology & Optometry (AREA)
Urology & Nephrology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)

UAA200503454A 2002-10-21 2003-10-17 Substituted tetralins and indanes and use thereof UA80561C2 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US42002602P	2002-10-21	2002-10-21
US49578803P	2003-08-15	2003-08-15
PCT/US2003/033371 WO2004037779A1 (en)	2002-10-21	2003-10-17	Substituted tetralins and indanes and their use

Publications (1)

Publication Number	Publication Date
UA80561C2 true UA80561C2 (en)	2007-10-10

Family

ID=32179777

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UAA200503454A UA80561C2 (en)	2002-10-21	2003-10-17	Substituted tetralins and indanes and use thereof

Country Status (28)

Country	Link
US (2)	US20040167211A1 (de)
EP (1)	EP1554240B1 (de)
JP (1)	JP4411275B2 (de)
KR (1)	KR100989394B1 (de)
CN (1)	CN100354259C (de)
AT (1)	ATE430728T1 (de)
AU (1)	AU2003279996B2 (de)
BR (1)	BR0315623A (de)
CA (1)	CA2502665A1 (de)
CY (1)	CY1110326T1 (de)
DE (1)	DE60327543D1 (de)
DK (1)	DK1554240T3 (de)
EA (1)	EA009554B1 (de)
ES (1)	ES2325783T3 (de)
HR (1)	HRP20050336B1 (de)
IL (1)	IL168147A (de)
ME (1)	MEP53108A (de)
MX (1)	MXPA05004192A (de)
NO (1)	NO332352B1 (de)
NZ (1)	NZ539451A (de)
PL (1)	PL376326A1 (de)
PT (1)	PT1554240E (de)
RS (1)	RS52079B (de)
SI (1)	SI1554240T1 (de)
TW (1)	TWI308563B (de)
UA (1)	UA80561C2 (de)
WO (1)	WO2004037779A1 (de)
ZA (1)	ZA200504064B (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20060094786A1 (en) *	2002-10-21	2006-05-04	Xiaoli Chen	Treating syndrome X with substituted tetralins and indanes
KR20050055773A (ko) *	2002-10-21	2005-06-13	얀센 파마슈티카 엔.브이.	치환된 테트라린 및 인단
US20060247314A1 (en) *	2002-10-21	2006-11-02	Xiaoli Chen	Substituted tetralins and indanes
CA2503405A1 (en) *	2002-10-21	2004-05-06	Janssen Pharmaceutica, N.V.	Treating syndrome x with substituted tetralins and indanes
AR048931A1 (es) *	2004-04-21	2006-06-14	Janssen Pharmaceutica Nv	Proceso para la preparacion de derivados de tetralina sustituida e indano sustituido y preparacion de intermediarios de sintesis
JP4619413B2 (ja) *	2004-10-12	2011-01-26	ファーマコペイアドラッグディスカバリー，インコーポレイテッド	肥満および関連障害の処置のための選択的メラニン濃縮ホルモンレセプターアンタゴニストとしての二環式化合物
AR095570A1 (es) *	2013-03-20	2015-10-28	Hoffmann La Roche	Derivados de urea

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU632809B2 (en) *	1989-05-25	1993-01-14	Takeda Chemical Industries Ltd.	Benzocycloalkane benzopyran and benzothiopyran urea derivatives and production thereof
GB9027023D0 (en)	1990-12-12	1991-01-30	Wellcome Found	Anti-atherosclerotic aryl compounds
JP3342491B2 (ja)	1993-08-06	2002-11-11	ファルマシア・アンド・アップジョン・カンパニー	選択的ドーパミンｄ３リガンドとしての２−アミノインダン類
GB9606805D0 (en)	1996-03-30	1996-06-05	Glaxo Wellcome Inc	Medicaments
EP1666587A1 (de)	1996-06-13	2006-06-07	Astellas Pharma Inc.	Zyclische lipopeptid acylase
GB9822473D0 (en) *	1998-10-16	1998-12-09	Glaxo Group Ltd	Chemical compounds
US6300339B1 (en)	1998-10-21	2001-10-09	Novo Nordisk A/S	Compounds, their preparation and use
TWI234557B (en)	1999-05-26	2005-06-21	Telik Inc	Novel naphthalene ureas as glucose uptake enhancers
JP2003523336A (ja) *	2000-02-18	2003-08-05	メルクエンドカムパニーインコーポレーテッド	糖尿病及び脂質障害のためのアリールオキシ酢酸
HUP0302306A3 (en) *	2000-10-05	2005-02-28	Bayer Ag	Propionic acid derivatives with ppar-alpha activating properties
WO2002044129A1 (fr) *	2000-11-29	2002-06-06	Kyorin Pharmaceutical Co., Ltd.	Dérivés d'acide carboxylique substitués
WO2002046146A1 (fr) *	2000-12-05	2002-06-13	Kyorin Pharmaceutical Co., Ltd.	Derives d'acide carboxylique substitues
AU2002233271A1 (en) *	2000-12-20	2002-07-01	Glaxo Group Limited	Substitued oxazoles and thiazoles as hppar alpha agonists
TWI241190B (en)	2001-02-13	2005-10-11	Aventis Pharma Gmbh	4-Fluoro-N-indan-2-yl benzamide and its use as pharmaceutical
BR0207285A (pt)	2001-02-15	2004-02-10	Pfizer Producs Inc	Agonistas de ppar
JP2004520397A (ja)	2001-02-15	2004-07-08	ファイザー・プロダクツ・インク	増殖性アクチベータ受容体（ｐｐａｒ）化合物
US6548538B2 (en)	2001-05-22	2003-04-15	Bayer Aktiengesellschaft	Propionic acid derivatives
UA82835C2 (en) *	2001-12-03	2008-05-26	Reddys Lab Ltd Dr	?-aryl-?-oxysubstituted propionuc acid derivatives and pharmaceutical composition based thereon
US20060094786A1 (en) *	2002-10-21	2006-05-04	Xiaoli Chen	Treating syndrome X with substituted tetralins and indanes
CA2503405A1 (en) *	2002-10-21	2004-05-06	Janssen Pharmaceutica, N.V.	Treating syndrome x with substituted tetralins and indanes
US20060247314A1 (en) *	2002-10-21	2006-11-02	Xiaoli Chen	Substituted tetralins and indanes
KR20050055773A (ko) *	2002-10-21	2005-06-13	얀센 파마슈티카 엔.브이.	치환된 테트라린 및 인단
AR048931A1 (es) *	2004-04-21	2006-06-14	Janssen Pharmaceutica Nv	Proceso para la preparacion de derivados de tetralina sustituida e indano sustituido y preparacion de intermediarios de sintesis

2003
- 2003-10-17 AU AU2003279996A patent/AU2003279996B2/en not_active Ceased
- 2003-10-17 EP EP03773302A patent/EP1554240B1/de not_active Expired - Lifetime
- 2003-10-17 HR HRP20050336AA patent/HRP20050336B1/hr not_active IP Right Cessation
- 2003-10-17 BR BR0315623-0A patent/BR0315623A/pt not_active IP Right Cessation
- 2003-10-17 KR KR1020057006805A patent/KR100989394B1/ko not_active Expired - Fee Related
- 2003-10-17 EA EA200500516A patent/EA009554B1/ru not_active IP Right Cessation
- 2003-10-17 DE DE60327543T patent/DE60327543D1/de not_active Expired - Lifetime
- 2003-10-17 RS YU20050320A patent/RS52079B/sr unknown
- 2003-10-17 SI SI200331635T patent/SI1554240T1/sl unknown
- 2003-10-17 ES ES03773302T patent/ES2325783T3/es not_active Expired - Lifetime
- 2003-10-17 PL PL03376326A patent/PL376326A1/xx not_active Application Discontinuation
- 2003-10-17 NZ NZ539451A patent/NZ539451A/en not_active IP Right Cessation
- 2003-10-17 US US10/688,379 patent/US20040167211A1/en not_active Abandoned
- 2003-10-17 ME MEP-531/08A patent/MEP53108A/xx unknown
- 2003-10-17 DK DK03773302T patent/DK1554240T3/da active
- 2003-10-17 JP JP2005501641A patent/JP4411275B2/ja not_active Expired - Fee Related
- 2003-10-17 AT AT03773302T patent/ATE430728T1/de active
- 2003-10-17 WO PCT/US2003/033371 patent/WO2004037779A1/en not_active Ceased
- 2003-10-17 CA CA002502665A patent/CA2502665A1/en not_active Abandoned
- 2003-10-17 CN CNB2003801060885A patent/CN100354259C/zh not_active Expired - Fee Related
- 2003-10-17 MX MXPA05004192A patent/MXPA05004192A/es active IP Right Grant
- 2003-10-17 UA UAA200503454A patent/UA80561C2/uk unknown
- 2003-10-17 PT PT03773302T patent/PT1554240E/pt unknown
- 2003-10-21 TW TW092129193A patent/TWI308563B/zh not_active IP Right Cessation
2005
- 2005-04-19 IL IL168147A patent/IL168147A/en unknown
- 2005-05-10 NO NO20052280A patent/NO332352B1/no not_active IP Right Cessation
- 2005-05-19 ZA ZA200504064A patent/ZA200504064B/en unknown
- 2005-06-03 US US11/145,119 patent/US7351857B2/en not_active Expired - Lifetime
2009
- 2009-08-04 CY CY20091100820T patent/CY1110326T1/el unknown

Also Published As

Publication number	Publication date
NO332352B1 (no)	2012-09-03
HRP20050336B1 (hr)	2013-06-30
CA2502665A1 (en)	2004-05-06
ZA200504064B (en)	2006-09-27
MEP53108A (en)	2011-05-10
PT1554240E (pt)	2009-06-17
IL168147A (en)	2010-11-30
CN100354259C (zh)	2007-12-12
WO2004037779A1 (en)	2004-05-06
HRP20050336A2 (en)	2006-11-30
ES2325783T3 (es)	2009-09-17
TW200418774A (en)	2004-10-01
SI1554240T1 (sl)	2009-10-31
EP1554240B1 (de)	2009-05-06
AU2003279996A1 (en)	2004-05-13
US7351857B2 (en)	2008-04-01
PL376326A1 (en)	2005-12-27
US20060074130A1 (en)	2006-04-06
KR20050071597A (ko)	2005-07-07
ATE430728T1 (de)	2009-05-15
NZ539451A (en)	2008-03-28
DE60327543D1 (de)	2009-06-18
MXPA05004192A (es)	2005-09-20
EA009554B1 (ru)	2008-02-28
CN1726187A (zh)	2006-01-25
EP1554240A1 (de)	2005-07-20
AU2003279996B2 (en)	2009-07-09
US20040167211A1 (en)	2004-08-26
DK1554240T3 (da)	2009-08-17
EA200500516A1 (ru)	2005-10-27
RS20050320A (sr)	2007-11-15
NO20052280L (no)	2005-06-24
TWI308563B (en)	2009-04-11
JP4411275B2 (ja)	2010-02-10
KR100989394B1 (ko)	2010-10-25
BR0315623A (pt)	2005-08-23
CY1110326T1 (el)	2015-01-14
RS52079B (sr)	2012-06-30
JP2006503917A (ja)	2006-02-02

Publication	Publication Date	Title
UA80561C2 (en)	2007-10-10	Substituted tetralins and indanes and use thereof
CN101283955B (zh)	2012-08-15	氨基酸类高含量防腐水溶液
CY1111708T1 (el)	2015-10-07	Συνθεση ελεγχομενης απελευθερωσης και μεθοδος παρασκευης αυτης
KR960700708A (ko)	1996-02-24	3,4-디아릴크로만을 이용한 뼈 손실의 억제방법(methdos for inhibiting bone loss with 3,4-diarylchroman)
WO2002034705A3 (en)	2002-07-11	C-nitroso compounds and use thereof
FR2719481A1 (fr)	1995-11-10	Composition à base de composés antifongiques et de composés antibactériens halogènes pour diminuer la chute des cheveux.
EP2161265A3 (de)	2010-06-02	Verbindungen mit selektiver inhibierender Wirkung für GSK3
ZA949191B (en)	1996-05-20	Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
MY139606A (en)	2009-10-30	Sustained-release composition and process for producing the same
IL171977A (en)	2010-12-30	Cyclic sulfonamide for inhibition of gamma-secretase, process for its preparation and a pharmaceutical composition comprising the same
RU2000131221A (ru)	2002-10-27	Новые аналоги жирных кислот для лечения диабета
CH616080A5 (de)	1980-03-14
MY135954A (en)	2008-07-31	Crystalline form of (s)-ethoxy-3-4-(2-4-methanesulfonyloxyphenyl ethoxy) phenyl] propanoic acid
EP1911757A3 (de)	2008-05-28	Verfahren zur Herstellung von 3-(1,3-Dihydroimidazol-2-thion-1-yl)-chromanen und thiochromanen als Dopamin-beta-hydroxylase Inhibitor
JP2002541133A (ja)	2002-12-03	安息香酸エステルから誘導された化合物、該化合物を含有する組成物及びその使用
EP0911331A3 (de)	2000-01-19	Substutierte Dibenzoxazepinverbindungen, pharmazeutische Zusammensetzungen, und Anwendungsmethoden
CN111588729A (zh)	2020-08-28	β-烟酰胺单核苷酸在预防脱发或促进毛发生长产品中的应用
RU2003116126A (ru)	2004-11-27	Лактамные соединения и их фармацевтическое использование
KR950701905A (ko)	1995-05-17	치환된 (아릴알킬아미노벤질)아미노프로피온아미드 유도체, 이의 제조방법 및 간질치료제, 신경보호제 및 우울증치료제로서의 이의 용도(Substituted (arylalkyla-minobenzyl)aminopropionamide derivatives, their preparation and use anti-epileptic, neuroprotective and antidepressant agents)
AR039163A1 (es)	2005-02-09	Besilato de venlafaxina
CA2438509A1 (en)	2002-08-29	Use of cyclohexenone derivatives for the manufacture of a medicament in the treatment of dysuria
NZ201217A (en)	1986-05-09	N-(2-aryl-2-hydroxyethyl)-n-(omega-(amino or cyano)alkoxyphenyl)
EP0647616A4 (de)	1995-08-16	Zink-tranexamat derivat.
CH694420A5 (fr)	2005-01-14	Collier anti-puces et anti-tiques pour chien et chat, à base de N-phénylpyrazole
EP0431154A1 (de)	1991-06-12	Wundheilmittel enthaltend 1-phenyl-2-aminoäthanolderivaten und calendula-tinktur